NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
1.050
-0.150 (-12.50%)
Oct 14, 2025, 4:00 PM EDT - Market closed
Company Description
NovaBay Pharmaceuticals, Inc. does not have significant operations.
Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | David Lazar |
Contact Details
Address: 2000 Powell Street, Suite 1150, eleventh floor Emeryville, California 94608 United States | |
| Phone | 510 899 8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P4090 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Elliot Lazar | Chief Executive Officer and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
| Justin M. Hall Esq., J.D. | Vice President of Business Dev., General Counsel, Chief Compliance Officer, Corporate Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 9, 2025 | 8-K | Current Report |
| Oct 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 23, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 23, 2025 | ARS | Filing |
| Sep 18, 2025 | 8-K | Current Report |
| Sep 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 10, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 4, 2025 | SCHEDULE 13D/A | Filing |
| Aug 26, 2025 | SCHEDULE 13D | Filing |